Time filter

Source Type

Mathrusri Annapurna M.,Gandhi Institute of Technology and Management | Nanda B.,Roland Institute of Pharmaceutical science
Journal of Pharmacy and Nutrition Sciences | Year: 2011

Abstract: A simple precise, accurate RP-HPLC method has been developed and validated for analysis of Zolmitriptan (ZLM). The separation and quantization were achieved on a 250 mm reversed phase column with a hydrophilic linkage between silica particles and hydrophobic alkyl chains. The mobile phase was constituted (flow rate 0.8 ml min-1) of eluant A (CH3OH) and eluant B (aqueous tetra butyl ammonium hydrogen sulphate) (pH 3.4; 10 mM) using isocratic elution with UV detection at 224 nm. The method showed good linearity for ZMT in the 1-100 μg mL-1 range with regression equation 15576x ± 99401 and correlation coefficient 0.999 respectively. The limit of quantitation (LOQ) and limit of detection (LOD) were found to be 0.8134 and 0.2687 μg mL-1 respectively. Finally the applicability of the method was validated according to ICH guidelines and can be applicable for the analysis of commercial dosage forms. Source

Akhter S.,Jamia Hamdard University | Ahmad J.,Jamia Hamdard University | Ahmad M.Z.,Najran University | Beg S.,Roland Institute of Pharmaceutical science | Ahmad F.J.,Jamia Hamdard University
Expert Opinion on Drug Delivery | Year: 2015

Introduction: Psoriasis is a T-cell mediated autoimmune inflammatory skin disease recognized by skin surface inflammation, epidermal proliferation, hyperkeratosis, angiogenesis and anomalous keratinization. Currently, various pharmacotherapies are available for it; however, pharmacotherapy based on conventional formulations can provide therapeutic benefits only to a limited extent. Recent advancement in nanotechnology-based nanomedicines has led to the possibility of improving the efficacy and safety of pharmacotherapeutic agents for psoriasis.Areas covered: This review covers the brief pathophysiology of psoriasis, available medications and its associated challenges in treatment. Collective accounts of various drugs acting on different molecular targets of psoriasis and the role of nanomedicines in their effective targeting are discussed. Moreover, newer approaches in psoriatic therapy such as combination drug targeting and physical techniques of topical permeation enhancement along with nanomedicines are also discussed.Expert opinion: Novel nanomedicines (such as liposomes, polymeric nanoparticles, etc.) have shown their potential in improving therapeutic benefits of antipsoriatic drugs by increasing their therapeutic efficacy with minimal toxicity. Nevertheless, while the results on animal models using nanomedicine-based drug targeting of psoriasis via different route seem promising, lack of sufficient evidence in a clinical setup is a constraint and more clinical studies on the efficacy and safety of nanomedicines in psoriasis therapy are required. © 2014 Informa UK, Ltd. Source

Patro V.J.,Roland Institute of Pharmaceutical science | Dinda S.C.,Berhampur University
Pharmacognosy Reviews | Year: 2012

Plants of genus Leucas (Lamiaceae) are widely distributed throughout Asia, Africa, and India. The plant is used in traditional medicine to cure many diseases such as cough, cold, diarrhea, and inflammatory skin disorder. A variety of phytoconstituents have been isolated from the Leucas species, which include lignans, flavonoids, coumarins, steroids, terpenes, fatty acids, and aliphatic long-chain compounds. Anti-inflammatory, analgesic, anti-diarrheal, antimicrobial, antioxidant, and insecticidal activities have been reported in the extracts of these plants and their phytoconstituents. An overview of the ethnobotanical, phytochemical, and pharmacological investigations on the Leucas species is presented in this review. Source

Annapurna M.M.,Gandhi Institute of Technology and Management | Mohapatro C.,Roland Institute of Pharmaceutical science | Narendra A.,Roland Institute of Pharmaceutical science
Journal of Pharmaceutical Analysis | Year: 2012

A stability-indicating high-performance liquid chromatographic method was developed and validated for the determination of Letrozole in tablet dosage forms. Reversed-phase chromatography was performed on Shimadzu Model LC-Class-Vp with Lichrocart/Lichrosphere 100 C-18 (250 mm×4.6 mm, 5 μm particle size) column with methanol: tetra butyl ammonium hydrogen sulfate (80:20V/V) as mobile phase at a flow rate of 1 mL/min with UV detection at 240 nm. Linearity was observed in the concentration range of 0.5-150 μg/mL (R 2=0.9998) with regression equation y=102582x43185. The limit of quantitation (LOQ) and limit of detection (LOD) were found to be 0.043 and 0.012 μg/mL respectively. The forced degradation studies were performed by using HCl, NaOH, H2O2, thermal and UV radiation. Letrozole is more sensitive towards alkaline conditions and very much resistant towards acidic, oxidative and photolytic degradations. The method was validated as per ICH guidelines. The RSD for intra-day (0.78-0.97) and inter-day (0.86-0.96) precision were found to be lesser than 1%. The percentage recovery was in good agreement with the labeled amount in the pharmaceutical formulations and the method is simple, specific, precise and accurate for the determination of Letrozole in pharmaceutical formulations. © 2012 Xi'an Jiaotong University. Source

Sahu K.,Roland Institute of Pharmaceutical science | Bisht Dr. S.S.,Roland Institute of Pharmaceutical science
International Journal of Pharma and Bio Sciences | Year: 2013

Parkinson's disease PARK1, caused by mutations in the SNCA gene, which codes for the protein alpha-synuclein. SNCA gene is analysed by different NCBI tools and bioinformatics softwares (ORF, Map Viewer, e-PCR, Vec screen, Genscan, BLAST, FASTA, MSA, ClustalW, bioedit software and phylodraw software). Then protein information and protein structures are analysed by different proteomics tools and different softwares (Protparam, Protscale, GOR, SOPMA, SignalP, NetNGly, NetOGly, NetAcet, NetPhos, sulfinator, SOSUI, bioedit software, SPDBV software, RASMOL 3D analysis software). Homology modelling of the protein is done using SPDBV (SWISS PDB VIEWER). Active site analysis is done through Q-site finder method and the active site amino acids are noted. Standard available market drugs targeting the protein were identified as Carbidopa, Dopamine, Levodopa, Memantine, and Apomorphine. 16 similar molecules for these standard molecules were modelled using Argus Lab software. A database is created with all these molecules in Vega ZZ software. Virtual screening of these drugs is done through protein-database docking method. QSAR analysis is done through Hyperchem software. UV & IR transitions are done through CAche software. Source

Discover hidden collaborations